[Date Prev][Date Next][Thread Prev][Thread Next][Date Index][Thread Index]

HIV/AIDS Update - Prezista label update includes 192-week safety, resistance and efficacy data

Title: HIV/AIDS Update - Prezista label update includes 192-week safety, resistance and efficacy data

FDA HIV/AIDS List Serve Image

You are receiving this message as a subscriber to the FDA HIV/AIDS electronic list serve. The purpose of the list serve is to relay important information about HIV/AIDS-related products and issues, including product approvals, significant labeling changes, safety warnings, notices of upcoming public meetings and alerts to proposed regulatory guidances for comment.

Please do not reply to this message.

Updates to the Prezista (darunavir) package insert, specifically sections: 6 Adverse Reactions, 12.4 Microbiology, 14 Clinical Studies and were approved on October 19, 2011 to include results from the 192-week safety, resistance and efficacy data from study TMC114-C211, “A randomized, controlled, open-label Phase 3 trial comparing PREZISTA/ritonavir 800/100 mg once daily versus lopinavir/ritonavir 800/200 mg per day (given as a twice daily or as a once daily regimen) in antiretroviral treatment-naïve HIV-1-infected adult subjects.”

In addition section 5.3 Severe Skin Reactions now includes the following text about PREZISTA/ritonavir + raltegravir containing regimens.

Rash occurred more commonly in treatment-experienced subjects receiving regimens containing PREZISTA/ritonavir + raltegravir compared to subjects receiving PREZISTA/ritonavir without raltegravir or raltegravir without PREZISTA/ritonavir. However, rash that was considered drug related occurred at similar rates for all three groups. These rashes were mild to moderate in severity and did not limit therapy; there were no discontinuations due to rash.

The complete revised label will be posted soon at Drugs@FDA.

Richard Klein
Office of Special Health Issues
Food and Drug Administration

Kimberly Struble
Division of Antiviral Drug Products
Food and Drug Administration

This email was sent to list-fda@xxxxxxxxxxx using GovDelivery, on behalf of: U.S. Food & Drug Administration (FDA) · 10903 New Hampshire Ave · Silver Spring, MD 20993 · 800-439-1420 Powered by GovDelivery

[Index of Archives]     [CDC News]     [NIH News]     [USDA News]     [Photo]     [Hot Springs Photos]     [Steve's Art]     [Camping in Yosemite]     [Yosemite Photos]     [PhotoForum]     [SB Lupus]     [STB]

  Powered by Linux